Risk of adverse cardiovascular outcomes among people with HIV and nonalcoholic fatty liver disease
Arunkumar Krishnan(Levine Cancer Institute), Saleh A. Alqahtani(Johns Hopkins University), Tinsay A. Woreta(Johns Hopkins University), Omar T. Sims(Apple (Israel)), Phani Keerthi Surapaneni(Jacksonville College)
Cited by 20
Related Papers
Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving.
|Endocrinology|1993|1.5k
A global research priority agenda to advance public health responses to fatty liver disease
|Journal of Hepatology|2023|132
Candida albicans estrogen-binding protein gene encodes an oxidoreductase that is inhibited by estradiol.
|Proceedings of the National Academy of Sciences|1994|112
The anti-cancer and anti-inflammatory actions of 1,25(OH)2D3
|Best Practice & Research Clinical Endocrinology & Metabolism|2011|109
Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality
|JAMA Network Open|2023|108